Testing enpatoran for lupus skin problems
Part of Immune system & allergy, Skin clinical trials.
This trial tests an oral drug called enpatoran for people with lupus that causes skin rashes (like discoid or subacute cutaneous lupus). The goal is to see if the drug can improve these skin symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lupus that affects your skin, like discoid or subacute cutaneous lupus, with or without systemic lupus.
- If you have systemic lupus, your skin symptoms must be active and moderate to severe (a score of at least 8 on a skin activity scale).
- Your lupus skin symptoms have been present for at least 6 months if you have systemic lupus.
- You are up to date on routine vaccinations (shingles vaccine is encouraged but not required).
- You do not have other active autoimmune diseases like rheumatoid arthritis or severe organ problems from lupus (like active kidney disease or seizures).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a drug called enpatoran can help people with lupus that causes skin rashes, like discoid lupus or subacute cutaneous lupus. It may be for those with or without systemic lupus.
This trial tests an experimental antibody injection (DB-2304) to see if it can improve lupus skin rashes and other lupus symptoms. It is for people with active lupus skin disease who have already tried standard treatments.
This study tests an experimental medicine called VENT-03 to see if it can improve skin lupus symptoms in adults. It compares VENT-03 against a placebo (a pill with no active drug) and includes a longer-term option where everyone can get the real drug. The goal is to find a new treatment for people whose lupus affects their skin.
This trial tests an experimental drug called ICP-488 for people with active cutaneous lupus erythematosus (CLE), a type of lupus that affects the skin. It aims to see if the drug can reduce skin inflammation and improve symptoms.
This Phase 2 study tests whether LNP023 can improve outcomes and safety in people with active lupus nephritis (lupus-related kidney inflammation), class III or IV. It may help by targeting the ongoing immune activity that is damaging the kidneys.
This trial tests two new drugs, BCD-256-1 and divozilimab, for people with systemic lupus erythematosus (SLE) who have active skin symptoms not controlled by current treatments. The goal is to see if they are safe and how the body processes them.
Hear when a new Systematic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.